Regulation
Rules, guidance and how the agencies work.
Stories
-
FDA draft guidance sets out how early-phase solid tumor protocols should handle eligibility, dosing and consent
A November 2026 FDA draft guidance for sponsors and clinical investigators recommends eligibility, dose escalation, consent and sampling practices for first-in-human and other early-phase solid tumor trials. Comments are due January 11, 2027.
-
CMS announces optional hold harmless period for Medicaid work requirement
CMS said the optional hold harmless period runs through June 30, 2027, giving states a transition period to modernize systems and improve the beneficiary experience. States that implement the hold harmless period will assess whether individuals meet the work requirement or are excluded from it, but they will not deny applications or disenroll otherwise eligible individuals solely for failure to meet the requirement.
-
FDA releases draft guidance on early-phase IND protocols for solid tumors
FDA announced the availability of a draft guidance titled "Early-Phase IND Protocol Recommendations for Solid Tumors" to provide recommendations for sponsors and investigators developing early-phase trials. Comments are due by January 11, 2027, and the guidance covers first-in-human protocols for drugs and biologic products with limited human experience, but does not address hematologic malignancies.
-
FDA actions, week of November 9, 2026: 4 approvals, 1 rule, 1 notice
The FDA published 6 actions in the week of November 9 to 15, 2026: 4 approval announcements, 1 final rule in the Federal Register and 1 notice in the Federal Register.
-
FDA partially grants petition to remove methylene chloride as color additive diluent
The order removes a solvent used as a diluent in inks for marking fruit and vegetables, effective January 11, 2027. Requests to remove ethylene dichloride and trichloroethylene from extraction solvents for annatto, paprika, and turmeric were denied because residues would be impurities not covered by the Delaney Clause.
-
FDA draft would require IDE applications for device trials to come in through eSTAR
An FDA draft guidance of October 28, 2026 would require IDE applications to be electronic submissions built in eSTAR, with no waivers and a transition of at least one year after the final guidance. Comments are due December 28, 2026.
-
FDA classifies external mechanical stimulator for congestion as class II
A final order has been issued to place the device for relieving congestion into category II, adding special controls. The action is intended to provide reasonable assurance of safety and effectiveness and to enhance patients' access to innovative devices by reducing regulatory burdens.
-
CMS codifies Medicare Drug Price Negotiation Program for 2029
On Nov. 5 2026, the Centers for Medicare & Medicaid Services issued a final rule (CMS-4215-F) that codifies the Negotiation Program for the initial price applicability year 2029 and beyond, effective Dec. 5 2026. The rule also establishes new policies for selecting up to 20 drugs for negotiation each year and clarifies procedures for manufacturers and the publication of negotiated maximum fair prices.
-
FDA classifies wearable vibration device for orthopedic use as class II
The FDA finalized an order classifying the wearable vibration device for orthopedic use into class II with special controls, stating the classification will provide a reasonable assurance of the safety and effectiveness of the device. The agency said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
-
FDA classifies mild cognitive impairment prognostic software as class II
The FDA issued a final order classifying the prognostic assessment software of mild cognitive impairment into class II with special controls, as stated in the Federal Register. The order notes that this classification should provide reasonable assurance of safety and effectiveness and may enhance patient access by reducing regulatory burdens.
-
CMS finalizes CY 2027 Medicare Physician Fee Schedule rule
The Centers for Medicare & Medicaid Services published a final rule on November 4, 2026 that finalizes policy changes for Medicare payments under the Physician Fee Schedule effective Jan. 1, 2027. The rule includes a +0.75% conversion factor for qualifying APM participants and a +0.25% factor for non-qualifying participants, with overall payment reductions of 1.83% and 2.31% respectively compared to CY 2026.
-
CMS finalizes broad Medicare integrity changes in home health final rule
CMS finalized a CY 2027 Home Health Prospective Payment System final rule that is expected to save taxpayers approximately $82 million annually by strengthening its ability to recover Medicare payments from noncompliant providers and suppliers. The rule also shortens the OASIS data submission deadline from 135 days to 45 days, potentially reducing the public reporting lag by up to three months.